Abstract
Background
Breast cancer is the most common malignant tumor among females around the world. It represents 1.7 million new cases per year and 25% of all types of cancers.
Objectives
Assessment of median overall survival in most aggressive subtypes of metastatic breast cancer (Triple –Ve and HER2+Ve) & to compare survival of metastatic HER2+Ve breast cancer in group received targeted versus that did not receive.
Patient and Methods
Multi institutional retrospective study for assessment of median OS in metastatic breast cancer for themost aggressive subtypes (HER2+Ve &Triple-Ve) at Ain Shams University Hospitals and El-Matarya teaching Hospital.
Results
Seventy-three metastatic breast cancer patients were included (31 Triple-Ve & 42 HER2+Ve) in the period between January 2014 and December 2016 At Ain Shams University Hospitals and El-Matarya teaching Hospital, we found that median OS for Triple negative group is 16 months with (95% CI 8.8- 23.6) , that for HER2+Ve group is 17 months with (95% CI 13.9 – 20.6) & for patients did not receive targeted therapy, median OS is 10 months (95% CI. 4-19.4,P.000).
Conclusion
From our study,we highlight that metastatic breast cancer patients (HER2+Ve subtype) &received targeted therapy, had the most superior survival outcome. so,targeted therapy must be included in first line treatment.
Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial